Delays in Surgery for Differentiated Thyroid Carcinomas: How Long Is Reasonable, and What Questions Remain?
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgac641 ↗Kurz gefasst
Editorial in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Jordan M Broekhuis und 1 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, Massachusetts 02215, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Papillary thyroid carcinoma is the most common type of thyroid cancer and is known to have excellent outcomes with standard of care treatment. The last decade has brought about societal guidelines recommending active surveillance for certain very low risk tumors, including papillary microcarcinomas, and additionally increasing use of thyroid lobectomy (1). Recently, the COVID 19 pandemic and other health systems pressures have resulted in delays in time to surgery for many operations that are considered elective or semielective. These issues have added importance to an already active discussion in the fields of endocrinology and endocrine surgery regarding appropriateness in delays to therapy for thyroid malignancies (2). In their recent manuscript, Zhou et al (3)evaluated the association of time to surgery with excellent treatment response at 1 year. This retrospective cohort study evaluated 871 patients with intermediate or high risk of recurrence who underwent total thyroidectomy and radioactive iodine ablation from 3 tertiary centers in China. Excellent treatment response was defined as no clinical, structural, or biochemical evidence of disease as defined by the American Thyroid Association guidelines (1). After stratifying by less than 6 months, 6 to 11 months, and 12 or more months’ time to surgery, there was no significant difference in the unadjusted proportion of patients with excellent treatment response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Harvard Medical School, Boston, Massachusetts 02215, USA.
- Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
ORCID-Profile: Benjamin C James
Zitieren
APA
Broekhuis, J. M., & James, B. C. (2023). Delays in Surgery for Differentiated Thyroid Carcinomas: How Long Is Reasonable, and What Questions Remain?. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgac641
Vancouver
Broekhuis JM, James BC. Delays in Surgery for Differentiated Thyroid Carcinomas: How Long Is Reasonable, and What Questions Remain?. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgac641
BibTeX
@article{Broekhuis2023,
author = {Broekhuis, Jordan M and James, Benjamin C},
title = {Delays in Surgery for Differentiated Thyroid Carcinomas: How Long Is Reasonable, and What Questions Remain?},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgac641}
}
EUVIMED